BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 22156612)

  • 1. Modeling a lethal prostate cancer variant with small-cell carcinoma features.
    Tzelepi V; Zhang J; Lu JF; Kleb B; Wu G; Wan X; Hoang A; Efstathiou E; Sircar K; Navone NM; Troncoso P; Liang S; Logothetis CJ; Maity SN; Aparicio AM
    Clin Cancer Res; 2012 Feb; 18(3):666-77. PubMed ID: 22156612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.
    Kleb B; Estécio MR; Zhang J; Tzelepi V; Chung W; Jelinek J; Navone NM; Tahir S; Marquez VE; Issa JP; Maity S; Aparicio A
    Epigenetics; 2016 Mar; 11(3):184-93. PubMed ID: 26890396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma.
    Chedgy EC; Vandekerkhove G; Herberts C; Annala M; Donoghue AJ; Sigouros M; Ritch E; Struss W; Konomura S; Liew J; Parimi S; Vergidis J; Hurtado-Coll A; Sboner A; Fazli L; Beltran H; Chi KN; Wyatt AW
    J Pathol; 2018 Oct; 246(2):244-253. PubMed ID: 30015382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
    Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
    Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.
    Tsai H; Morais CL; Alshalalfa M; Tan HL; Haddad Z; Hicks J; Gupta N; Epstein JI; Netto GJ; Isaacs WB; Luo J; Mehra R; Vessella RL; Karnes RJ; Schaeffer EM; Davicioni E; De Marzo AM; Lotan TL
    Clin Cancer Res; 2015 Dec; 21(24):5619-29. PubMed ID: 26246306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles.
    Aparicio A; Tzelepi V; Araujo JC; Guo CC; Liang S; Troncoso P; Logothetis CJ; Navone NM; Maity SN
    Prostate; 2011 Jun; 71(8):846-56. PubMed ID: 21456067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.
    Aparicio AM; Shen L; Tapia EL; Lu JF; Chen HC; Zhang J; Wu G; Wang X; Troncoso P; Corn P; Thompson TC; Broom B; Baggerly K; Maity SN; Logothetis CJ
    Clin Cancer Res; 2016 Mar; 22(6):1520-30. PubMed ID: 26546618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small cell carcinoma of the prostate: an immunohistochemical study.
    Yao JL; Madeb R; Bourne P; Lei J; Yang X; Tickoo S; Liu Z; Tan D; Cheng L; Hatem F; Huang J; Anthony di Sant'Agnese P
    Am J Surg Pathol; 2006 Jun; 30(6):705-12. PubMed ID: 16723847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of prostatic small-cell neuroendocrine carcinoma.
    Clegg N; Ferguson C; True LD; Arnold H; Moorman A; Quinn JE; Vessella RL; Nelson PS
    Prostate; 2003 Apr; 55(1):55-64. PubMed ID: 12640661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer.
    Friedlander TW; Roy R; Tomlins SA; Ngo VT; Kobayashi Y; Azameera A; Rubin MA; Pienta KJ; Chinnaiyan A; Ittmann MM; Ryan CJ; Paris PL
    Cancer Res; 2012 Feb; 72(3):616-25. PubMed ID: 22158653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
    Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
    BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERG gene rearrangements are common in prostatic small cell carcinomas.
    Lotan TL; Gupta NS; Wang W; Toubaji A; Haffner MC; Chaux A; Hicks JL; Meeker AK; Bieberich CJ; De Marzo AM; Epstein JI; Netto GJ
    Mod Pathol; 2011 Jun; 24(6):820-8. PubMed ID: 21336263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers.
    Simon RA; di Sant'Agnese PA; Huang LS; Xu H; Yao JL; Yang Q; Liang S; Liu J; Yu R; Cheng L; Oh WK; Palapattu GS; Wei J; Huang J
    Hum Pathol; 2009 Feb; 40(2):252-8. PubMed ID: 18835619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PC3 is a cell line characteristic of prostatic small cell carcinoma.
    Tai S; Sun Y; Squires JM; Zhang H; Oh WK; Liang CZ; Huang J
    Prostate; 2011 Nov; 71(15):1668-79. PubMed ID: 21432867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate.
    Park JW; Lee JK; Witte ON; Huang J
    Mod Pathol; 2017 Sep; 30(9):1262-1272. PubMed ID: 28621319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
    Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
    Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.
    Schelling LA; Williamson SR; Zhang S; Yao JL; Wang M; Huang J; Montironi R; Lopez-Beltran A; Emerson RE; Idrees MT; Osunkoya AO; Man YG; Maclennan GT; Baldridge LA; Compérat E; Cheng L
    Hum Pathol; 2013 Oct; 44(10):2227-33. PubMed ID: 23850495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
    Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
    J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.
    Wang L; Williamson SR; Zhang S; Huang J; Montironi R; Davison DD; Wang M; Yao JL; Lopez-Beltran A; Osunkoya AO; MacLennan GT; Baldridge LA; Du X; Cheng L
    Mol Carcinog; 2015 Sep; 54(9):900-7. PubMed ID: 24777847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
    Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
    Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.